左西孟旦联合西地兰治疗顽固性心力衰竭的临床疗效及安全性分析

Analysis of clinical efficacy and safety of levosimendan combined with cedilanid in the treatment of refractory heart failure

目的探究左西孟旦联合西地兰治疗顽固性心力衰竭的临床疗效及安全性。方法选取2021年1月至2022年3月抚州市第一人民医院收治的60例顽固性心力衰竭患者作为研究对象,随机分为对照组与实验组,每组30例。对照组在常规治疗基础上联合西地兰治疗,实验组在对照组基础上联合左西孟旦治疗。比较两组临床疗效、心功能相关指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDd)、左心室收缩末期内径(LVESd)、B型尿钠肽(BNP)和心脏指数(CI)]及不良反应发生率。结果实验组治疗总有效率为96.67%,高于对照组的73.33%,差异有统计学意义(P<0.05)。治疗后,两组LVEF、CI均高于治疗前,LVEDd、LVESd均短于治疗前,BNP水平低于治疗前,且实验组LVEF、CI水平均高于对照组,LVEDd、LVESd均短于对照组,BNP水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论左西孟旦联合西地兰治疗顽固性心力衰竭能明显提高病情治疗的疗效,有效改善患者心功能,且治疗安全性较高,值得临床推广应用。

Objective To explore the clinical efficacy and safety of levosimendan combined with cedilanid in the treatment of refractory heart failure.Methods 60 patients with refractory heart failure treated in the First People's Hospital of Fuzhou from January 2021 to March 2022 were se-lected as the research subjects,and they were randomly divided into the control group and the experimental group,with 30 cases in each group.The control group was treated with cedilanid on the basis of conventional treatment,and the experimental group was treated with levosimendan on the ba-sis of the control group.The clinical efficacy,cardiac function related indexes(left ventricular ejection fraction[LVEF],left ventricular end-diastolic diameter[LVEDd],left ventricular end-systolic diameter[LVESd],B-type natriuretic peptide[BNP]and cardiac index[CI])and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the experimental group was 96.67%,which was higher than 73.33%in the control group,and the difference was statistically significant(P<0.05).After treatment,LVEF and CI of the two groups were higher than those before treatment,LVEDd and LVESd were shorter than those before treatment,BNP level was lower than that before treat-ment,and LVEF and CI levels in the experimental group were higher than those in the control group,LVEDd and LVESd were shorter than those in the control group,BNP level was lower than that in the control group,the differences were statistically significant(P<0.05).There was no signifi-cant difference in the incidence of adverse reactions between the two groups.Conclusion Levosimendan combined with cedilanid in the treatment of intractable heart failure can significantly improve the curative effect of the disease,effectively improve the cardiac function of patients,and the treatment safety is high,which is worthy of clinical promotion and application.